



## Amendments to the Claims

1. (currently amended) A compound represented by formula (I), or a pharmaceutically acceptable salt or a prodrug derivative thereof:



wherein;


R and R' are independently C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>4</sub>-C<sub>5</sub> fluoroalkyl, or together R and R' form a substituted or unsubstituted, saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms;

R<sub>PH</sub> is hydrogen or methyl;

R1 and R2 are independently selected from the group consisting of hydrogen, halo, or C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>4</sub>-C<sub>5</sub> fluoroalkyl, O-C<sub>4</sub>-C<sub>5</sub> alkyl, S-C<sub>4</sub>-C<sub>5</sub> alkyl, O-C<sub>4</sub>-C<sub>5</sub> fluoroalkyl, CN, NO<sub>2</sub>, acetyl, S-C<sub>4</sub>-C<sub>5</sub> fluoroalkyl, C<sub>2</sub>-C<sub>5</sub> alkenyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, and C<sub>3</sub>-C<sub>5</sub> cycloalkenyl;

L<sub>1</sub> is -(CH<sub>2</sub>)<sub>m</sub>-O-;

and L<sub>2</sub> is -(CH<sub>2</sub>)<sub>m</sub>CH(OH)- or -(CH<sub>2</sub>)<sub>m</sub>C(O)-; and L<sub>3</sub> are independently divalent linking groups independently selected from the group consisting of



where m is 0, 1 or 2, X<sub>1</sub> is oxygen or sulfur, and each R40 is independently hydrogen, C<sub>1</sub>-C<sub>5</sub>-alkyl, or C<sub>1</sub>-C<sub>5</sub>-fluoroalkyl;

R<sub>B</sub> is

a branched C<sub>3</sub>-C<sub>5</sub> alkyl,  
3-methyl-3-hydroxypentyl,  
3-methyl-3-hydroxypentenyl,  
3-methyl-3-hydroxypentynyl,  
3-ethyl-3-hydroxypentyl,  
3-ethyl-3-hydroxypentenyl,  
3-ethyl-3-hydroxypentynyl,  
3-ethyl-3-hydroxy-4-methylpentyl,  
3-ethyl-3-hydroxy-4-methylpentenyl,  
3-ethyl-3-hydroxy-4-methylpentynyl,  
3-propyl-3-hydroxypentyl,  
3-propyl-3-hydroxypentenyl,  
3-propyl-3-hydroxypentynyl,  
1-hydroxy-2-methyl-1-(methyl ethyl)propyl,  
3-methyl-3-hydroxy-4,4-dimethylpentyl,  
3-methyl-3-hydroxy-4,4-dimethylpentenyl,  
3-methyl-3-hydroxy-4,4-dimethylpentynyl,  
3-ethyl-3-hydroxy-4,4-dimethylpentenyl,  
3-ethyl-3-hydroxy-4,4-dimethylpentynyl,  
4,4-dimethyl-3-hydroxypropyl,  
1-hydroxyeyeyelopentenyl,  
1-hydroxyeyelohexenyl,  
1-hydroxyeyeloheptenyl,  
1-hydroxyeyeloctenyl,  
1-hydroxyeyelopropyl,  
1-hydroxyeyelobutyl,  
1-hydroxyeyelopentyl,  
1-hydroxyeyelohexyl,  
1-hydroxyeyeloheptyl, or  
1-hydroxyeyeloctyl;

provided, however, that when

R<sub>B</sub> is

3-methyl-3-hydroxypentyl,  
 3-methyl-3-hydroxypentenyl,  
 3-methyl-3-hydroxypentynyl,  
 3-ethyl-3-hydroxypentyl,  
 3-ethyl-3-hydroxypentenyl,  
 3-ethyl-3-hydroxypentynyl,  
 4,4-dimethyl-3-hydroxypropyl,

3-ethyl-3-hydroxy-4-methylpentyl,  
 3-ethyl-3-hydroxy-4-methylpentenyl,  
 3-ethyl-3-hydroxy-4-methylpentynyl,  
 3-propyl-3-hydroxypentyl,  
 3-propyl-3-hydroxypentenyl,  
 3-propyl-3-hydroxypentynyl,  
 3-methyl-3-hydroxy-4,4-dimethylpentyl,  
 3-methyl-3-hydroxy-4,4-dimethylpentenyl,  
 3-methyl-3-hydroxy-4,4-dimethylpentynyl,  
 3-ethyl-3-hydroxy-4,4-dimethylpentyl,  
 3-ethyl-3-hydroxy-4,4-dimethylpentenyl,  
 3-ethyl-3-hydroxy-4,4-dimethylpentynyl, or  
 1-hydroxy-2-methyl-1-(methyl ethyl)propyl;

then L<sub>1</sub> and L<sub>2</sub> combine as a bond; and

R<sub>C</sub> is

-O-SO<sub>2</sub>-(R50)

— where R50 is

-C<sub>1-3</sub>alkyl, -CF<sub>3</sub>, or -(CH<sub>2</sub>)<sub>1-2</sub>CF<sub>3</sub>;  
 -S-C<sub>1-3</sub>alkyl, -SO<sub>2</sub>-C<sub>1-3</sub>alkyl,  
 -(CH<sub>2</sub>)<sub>1-2</sub>C(O)NHMe;  
 -(CH<sub>2</sub>)<sub>1-2</sub>CO<sub>2</sub>H; or

-NH-SO<sub>2</sub>-(R50)

where R50 is

-C<sub>1-3</sub>alkyl, -CF<sub>3</sub>, or -(CH<sub>2</sub>)<sub>1-2</sub>CF<sub>3</sub>,  
 -S-C<sub>1-3</sub>alkyl, -SO<sub>2</sub>-C<sub>1-3</sub>alkyl;

—(CH<sub>2</sub>)<sub>4-2</sub>CO<sub>2</sub>H,  
 —(CH<sub>2</sub>)<sub>4-2</sub>C(O)NHMe, or  
N(CH<sub>3</sub>)-SO<sub>2</sub>-C<sub>1-2</sub>alkyl; or  
-N(SO<sub>2</sub>R51)<sub>2</sub>

where each R51 is independently,


—C<sub>1-3</sub>alkyl, —CF<sub>3</sub>, or —(CH<sub>2</sub>)<sub>1-2</sub>CF<sub>3</sub>,  
 —(CH<sub>2</sub>)<sub>4-2</sub>C(O)NHMe,  
—S-C<sub>1-3</sub>alkyl, SO<sub>2</sub>-C<sub>1-3</sub>alkyl, or  
—(CH<sub>2</sub>)<sub>4-2</sub>CO<sub>2</sub>H.

2. (currently amended) A compound or pharmaceutically acceptable salt or prodrug thereof according to Claim 1 wherein R<sub>PH</sub> is hydrogen.

3-4. (canceled)


5. (currently amended) A compound or a pharmaceutically acceptable salts or an ester prodrug derivative thereof according to Claim 1 represented by the structural formulae M-1 to M-31 as follows:

M-1)




,

M-2)




,

M-3)




,

M-4)




,

M-5)




,

M-6)




,

M-7)




,

M-8)




,

M-9)




,

M-11)




,

M-12)




,

M-13)




,

M-14)




,

M-15)




,

M-16)




,

M-17)




,

M-18)




,

M-19)




,

M-20)




,

M-22)




,

M-23)




,

M-24)




,

M-25)




,

M-28)




,

M-29)




,

M-30)



, or


M-31)



,


6. (currently amended) A compound or a pharmaceutically acceptable salt or an ester prodrug derivative thereof according to Claim 1 represented by the structural formulae M-32 to M-50 as follows:

M-32)




,

M-34)




,

M-35)




,

M-36)




,

M-37)




,


M-38)




M-39)




M-40)




M-41)




M-42)




M-43)




M-44)




M-45)




M-46)




M-47)




M-48)



M-49)





M-50)




7. (canceled)

8. (Currently Amended) A compound according to Claim 1 represented by the a formula below:



, or



9-15. (canceled)

16. (previously presented) A pharmaceutical formulation comprising the compound according to Claim 1 together with a pharmaceutically acceptable carrier or diluent.

17-18. (canceled)

19. (original) A formulation for treating psoriasis comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 1;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

- a. topical glucocorticoids ,
- b. salicylic acid,
- c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

20. (canceled)

21. (currently amended, withdrawn) A method of treating a mammal for -to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Alopecia , Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprevention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host graft rejection, Hyperealeemia , Type II diabetes, Leukemia, Multiple selerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, or seborrheic dermatitis Skin cancer, Systemic lupus erythematosus; Skin cell damage from Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles; wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1.

22. (withdrawn) The method of claim 21 for the treatment of psoriasis.

23. (withdrawn) The method of claim 21 for the treatment of osteoporosis.


24-25. (canceled)

26. (currently amended, withdrawn) A method of treating or preventing disease states

mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound according to claim 1.

27-32. (canceled)

33. (new) A compound represented by formula (II) or a pharmaceutically acceptable salt thereof:




wherein;

R2 and R2' are independently methyl or ethyl;

R21 and R22 are independently selected from: hydrogen, methyl, ethyl, or -Cl,


R2B is 3,3-dimethyl-2-hydroxybutoxy or 3,3-dimethyl-2-oxobutoxy; and

R2C is



where Q is -O- or -NH-.

34. (new) A compound represented by formula (III) or a pharmaceutically acceptable salt thereof:




wherein;

R3 and R3' are independently methyl or ethyl;


R31 and R32 are independently selected from: hydrogen, methyl, ethyl, or -Cl,

R3<sub>B</sub> is 3,3-dimethyl-2-hydroxybutoxy or 3,3-dimethyl-2-oxobutoxy; and


R3<sub>C</sub> is




or




35. (new) A compound represented by a formula below:



36. (new) A compound represented by a formula below:



37. (new) A compound represented by a formula below:



38. (new) A pharmaceutical formulation comprising the compound according to one of claims 35, 36 or 37 together with a pharmaceutically acceptable carrier or diluent.

39. (new) A method of treating a mammal for Osteoporosis, Psoriasis, Scleroderma, or seborrheic dermatitis wherein the method comprises administering a pharmaceutically effective amount of at least the compound of according to one of claims 35, 36, or 37.

40. (new) The method of claim 39 for the treatment of psoriasis.

41. (new) The method of claim 39 for the treatment of osteoporosis.